Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
Researchers want to see how well cabozantinib works to treat meningioma, a type of brain tumor. The people in this study have meningiomas that came back or keep growing even after treatment.
The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:
Researchers are assessing a CAR T cell therapy to treat acute lymphoblastic leukemia (ALL) that keeps growing even with treatment. With CAR T cell therapy, some of your own T cells (a type of white blood cell) are removed. They are genetically modified (changed) in a lab to recognize your own cancer cells. The altered T cells, called CAR T cells, are then returned to your body to find and kill cancer cells. This treatment is a form of immunotherapy.
The purpose of this study is to assess the safety and effectiveness of combining three drugs to treat people with an IDH-mutant glioma that came back after chemotherapy or surgery. The three medications are pembrolizumab, olaparib, and temozolomide. 
Glioblastomas that have an "unmethylated" MGMT gene are less likely to respond to the standard chemotherapy drug temozolomide. In this study, researchers are comparing three investigational treatments (abemaciclib, CC-115, and neratinib) with the standard treatment (temozolomide and radiation therapy) in patients newly diagnosed with glioblastoma.
Researchers are assessing obinutuzumab in people with primary central nervous system lymphoma (PCNSL) whose cancer responded to initial treatment. They want to see if obinutuzumab increases the time without the disease returning or getting worse. This type of treatment is called maintenance therapy.
After a stem cell transplant, a condition called chronic graft-versus-host disease (cGVHD) can occur. The new donor immune cells (like T cells and B cells) attack the recipient's healthy tissues, thinking they are foreign. It usually starts around 100 days after the transplant, but it can begin earlier or later.
Researchers are doing this study to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab is a safe treatment. They also want to know if receiving this combination treatment before surgery may allow patients to forgo the standard radiation treatment given after surgery.
BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
